Skip to main content
Equibles
ALNY logo

ALNY · Alnylam Pharmaceuticals, Inc. · Metrics

Track ALNY — free

Use ALNY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALNY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$165.04 +8.39 (+5.36%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$22.11B
Shares
133.94M
Volume · Nov 13 3.59M Avg daily vol (3M) 2.04M

ALNY metrics

97 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$165.04
Market cap
$22.11B

Price action

23 metrics
Price change (1W)
+5.8%
Price change (30D)
-29.5%
Price change (3M)
-27.8%
Price change (6M)
-42.5%
Price change (YTD)
-58.5%
Price change (1Y)
-63.6%
Trailing year
Price change (5Y)
-3.4%
52-week high
$473.29
52-week low
$151.64
Change from 52-week high
-65.1%
Change from 52-week low
+8.8%
Annualized volatility
54.6%
Annualized volatility (3M)
67.0%
Implied volatility (30D)
50.3%
IV rank (1Y)
34.0
IV percentile (1Y)
71.4
Beta
0.6
RSI (14D)
34.6
Price vs SMA 50
-24.7%
Price vs SMA 200
-40.1%
Avg volume (3M)
2.04M
Relative volume
1.8
Average dollar volume
$424.64M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
133.94M

Valuation

12 metrics
P / E (TTM)
8.5
Trailing earnings · reciprocal yield 11.7%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.4×
reciprocal yield 22.7%
P / book
6.1
reciprocal yield 16.3%
FCF yield
3.6%
TTM · current market cap
Buyback yield
—
P / FCF
27.4
reciprocal yield 3.6%
P / operating cash flow
23.1
reciprocal yield 4.3%
Earnings yield
12.0%

Historical valuation

8 metrics
P / E historical average (3Y)
441.9×
reciprocal yield 0.2%
P / E historical average (5Y)
441.9×
reciprocal yield 0.2%
EV / revenue historical average (3Y)
21.8×
reciprocal yield 4.6%
EV / revenue historical average (5Y)
21.8×
reciprocal yield 4.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
77.4%
Operating margin
19.5%
Trailing 12 months
Net margin
52.8%
Gross profit (TTM)
$3.88B
Operating profit (TTM)
$977.59M
Net income (TTM)
$2.65B
Trailing 12 months
Diluted EPS (TTM)
$19.32
FCF margin
16.1%
Effective tax rate
-239.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$36.13
Gross profit per diluted share (TTM)
$27.95
Operating profit per diluted share (TTM)
$7.06
EBITDA per diluted share (TTM)
$7.46
Net income per diluted share (TTM)
$19.17
Operating cash flow per diluted share (TTM)
$6.89
Free cash flow per diluted share (TTM)
$5.81
Capital expenditures per diluted share (TTM)
$1.08
R&D per diluted share (TTM)
$11.23
Stock compensation per diluted share (TTM)
$2.22
Book value per share
$8.06

Growth

11 metrics
Revenue growth YoY
+16.7%
Year over year
Net income growth YoY
+640.5%
Revenue (TTM)
$5.01B
Trailing 12 months
EPS growth YoY
+634.6%
Shares change YoY
+0.5%
Year over year · more shares
Revenue CAGR (3Y)
+53.0%
Revenue CAGR (5Y)
+49.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
73.5%
Return on assets
33.1%
Debt / equity
—
Current ratio
2.5
EBITDA (TTM)
$1.03B
Free cash flow (TTM)
$806.31M
Quick ratio
2.4
Interest coverage
3.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.75B
Total assets
$7.99B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$955.94M
Capital expenditures (TTM)
$149.64M
R&D (TTM)
$1.56B
SG&A (TTM)
$1.34B
Stock compensation (TTM)
$307.53M
R&D / revenue
31.1%
Stock compensation / revenue
6.1%

Ownership (13F)

9 metrics
13F filers
796
13F filer change QoQ
-3
Institutional ownership
101.2%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.1%
Holder tenure
18.0
Price vs estimated holder cost
+0.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.4%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
36 / 100

Insider activity

2 metrics
Net insider buying (90D)
$144,271
Insider-sentiment score
76 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1178670 CUSIP 02043Q107 13F (30d) 589 filings 542 filers Visit website Investor relations